Regulation of nanotechnology

Regulation begins by asking what a nanomaterial is and whether its nanoscale form creates different risks from the same substance in bulk form. Size, shape, surface area, surface chemistry, solubility, persistence, and biological behavior can all affect hazard and exposure. Definitions therefore vary: some emphasize dimensions, while others include materials deliberately produced with novel properties. The OECD coordinates testing methods and risk-assessment work, but national authorities retain legal responsibility.¹

Most systems regulate an article according to its use and exposure route. A nanoparticle in a medicine may be reviewed under pharmaceutical law; the same substance in a coating may fall under chemicals or product-safety rules. Regulators commonly require identity and characterization data, toxicology, environmental fate, manufacturing controls, labeling where justified, and post-market monitoring. This product-by-product approach avoids treating every nanoscale material as inherently dangerous while permitting additional scrutiny where properties or exposure differ.

Regulatory approaches differ in legal structure but converge on risk assessment, information gathering, and exposure control. In the United States, the Food and Drug Administration considers nanotechnology within existing product authorities and advises developers to consult early when nanoscale features may alter safety or effectiveness. The Environmental Protection Agency addresses certain nanomaterials under the Toxic Substances Control Act and regulates pesticide products through its established pesticide framework.

In the European Union, nanomaterials are principally handled through chemicals, cosmetics, food, medicines, and worker-protection legislation. The EU’s chemicals regime, REACH, requires information for relevant substances, while sectoral rules may impose specific notification or labeling duties. Canada, Australia, Japan, and other jurisdictions likewise combine general chemical law with agency guidance, inventories, reporting requirements, or targeted standards rather than a single comprehensive statute.

Effective oversight depends on measuring both hazard and real-world exposure. Occupational agencies such as NIOSH emphasize engineering controls, ventilation, containment, respiratory protection, training, and health surveillance for workers who handle engineered nanomaterials.² Risk assessors examine inhalation, ingestion, dermal contact, injection, environmental release, persistence, and transformation across a product’s life cycle.

Testing is difficult because nanomaterials can change during dispersion, storage, use, or contact with biological and environmental media. Standard toxicology methods may need modified protocols for agglomeration, dissolution, dosimetry, and interference with assays. International guidance seeks comparable terminology and test methods, but gaps remain for complex structures such as nanotubes, nanocomposites, and materials that release nanoscale fragments. Regulatory decisions therefore often combine laboratory evidence, exposure modeling, manufacturing information, and precautionary controls rather than relying on one test.

Some of the most consequential regulatory questions concern materials that are not marketed as “nanotechnology.” A conventional product may generate nanoscale particles through abrasion, combustion, weathering, or degradation, while a deliberately engineered nanomaterial may be embedded so securely that consumer exposure is negligible. Regulators must distinguish the material as manufactured from particles released during use and disposal.

Another overlooked issue is that legal identity can follow a substance across jurisdictions imperfectly: one authority may regulate a material by particle size, another by function, and a third by its chemical composition. Nanomedicine also creates boundary problems because a nanoscale carrier, active ingredient, device, and combination product can trigger different review pathways. International bodies including the World Health Organization and OECD support evidence sharing, but confidential business information, rapidly changing formulations, limited long-term epidemiology, and uneven laboratory capacity continue to complicate transparent global governance.¹

Engineered nanomaterial

A material deliberately produced with external dimensions or internal structures at the nanoscale, often to obtain distinctive properties.

Nanosafety

Research and policy concerned with the potential health and environmental effects of nanomaterials.

REACH

The European Union system for registering, evaluating, authorizing, and restricting chemicals.

Life-cycle assessment

Evaluation of impacts and exposures from material production through use, disposal, or recycling.